Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/s3s3t8/personalized ) ... report "Personalized Medicine - Scientific and Commercial ... The aim of personalized medicine or individualized ... the right patient and, in some cases, even ... according to his/her genotype. This report describes the ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)... Elsevier,s DirectCourse online curricula ... training to comply with new CMS requirements   ... new crosswalk tool to help providers of ... direct service workers as a means to comply with ... CMS amended the regulations, effective March 17, ...
(Date:3/3/2015)... March 3, 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... with a focus on protecting the microbiome, announced today that ... present at the 27th Annual ROTH Conference being held on ... in Dana Point, CA. ... 2015 at 1:00 p.m. (Pacific Time). A live ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... York, May 26, 2012 Sanofi ... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today ... trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients ... subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase ...
... decades, neurologists have known that a diet high in fat ... resist drug therapy. But how the diet worked, and why, ... York Times Magazine called it "Epilepsy,s Big, Fat Miracle." ... School have proposed an answer, linking resistance to seizures to ...
... growth of crystals, do nanoparticles act as "artificial atoms" ... structures? This is the contention of a major but ... researchers at the U.S. Department of Energy (DOE),s Lawrence ... and point the way to energy devices of the ...
Cached Biology Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 2Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 3Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 4Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 5Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 7Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 8Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 9Reverse engineering epilepsy's 'miracle' diet 2Reverse engineering epilepsy's 'miracle' diet 3Nanoparticles seen as artificial atoms 2Nanoparticles seen as artificial atoms 3
(Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
(Date:1/22/2015)... NEW YORK and POINT ROBERTS, Washington ... global news source covering leading sectors including technology and tech ... Personal Privacy marketplace featuring master pickpocket and security consultant ... wallet is stolen and talks about the Wocket™ biometric smart ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... In the course of doing research on the mosquito-borne ... Virginia Tech researchers have discovered an inconvenient truth about ... used to detect and measure replicating viral RNA in ... using for ssqPCR is unreliable. The research appears ...
... Healthy eating, not supplements, is the best way to ... dietitian and researcher. As with vitamins, it,s best to ... taking often expensive and potentially ineffective supplements, says Gail Cresci, ... are buying stuff like crazy that is probably not even ...
... Researchers at the Michael & Susan Dell Center for ... of Public Health Austin Regional Campus found the obesity prevention ... in Texas in decreasing the prevalence of childhood obesity. ... Dell Center for Healthy Living, examined regional changes of child ...
Cached Biology News:Widely used virus assay shown unreliable when compared to other methods 2Eating right, not supplements, is best at keeping your good bacteria healthy, dietitian says 2Eating right, not supplements, is best at keeping your good bacteria healthy, dietitian says 3El Paso County serves as a model for obesity prevention, according to UT School of Public Health study 2El Paso County serves as a model for obesity prevention, according to UT School of Public Health study 3
ZBP-89 (S-15)...
... Physical form: Lyophilized ... salts Preparation Unit Definition: ... 1.0μmole of 2-phosphoglycerate to ... pH7.4 at 25 C. ...
... ion exchange media are ... high binding capacity. The ... a strong cation exchanger ... of 120 micrometers. Fully ...
... form: Essentially sulfate-free, powder containing carbohydrate ... Preparation Unit Definition: One unit will ... -fructose 6-phosphate to D -glucose ... at 25 C. Chem ...
Biology Products: